BioLife Solutions, Inc. (NASDAQ:BLFS) Holdings Increased by Curi RMB Capital LLC

Curi RMB Capital LLC lifted its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 433,815 shares of the medical equipment provider’s stock after acquiring an additional 11,882 shares during the period. Curi RMB Capital LLC owned 0.94% of BioLife Solutions worth $11,262,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in BLFS. FMR LLC lifted its position in BioLife Solutions by 470.6% in the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 10,983 shares during the period. Stifel Financial Corp lifted its holdings in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 670 shares during the period. State Street Corp boosted its stake in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares in the last quarter. Barclays PLC grew its holdings in BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after acquiring an additional 10,803 shares during the period. Finally, Geode Capital Management LLC raised its position in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. StockNews.com upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, April 8th. Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.17.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $21.91 on Friday. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -20.67 and a beta of 1.93. BioLife Solutions, Inc. has a 1 year low of $15.72 and a 1 year high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $24.62 and a 200 day simple moving average of $25.26.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period last year, the business earned ($0.21) EPS. As a group, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BioLife Solutions news, CFO Troy Wichterman sold 25,687 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $582,067.42. Following the completion of the sale, the chief financial officer now directly owns 189,242 shares in the company, valued at $4,288,223.72. This represents a 11.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Aby J. Mathew sold 1,597 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,925.00. Following the sale, the executive vice president now owns 260,601 shares of the company’s stock, valued at approximately $6,515,025. The trade was a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,127 shares of company stock valued at $1,676,533 over the last quarter. Insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.